Resource Type

Journal Article 700

Conference Videos 52

Conference Information 1

Year

2024 63

2023 111

2022 140

2021 137

2020 71

2019 19

2018 15

2017 14

2016 30

2015 19

2014 11

2013 10

2012 20

2011 8

2010 11

2009 21

2008 17

2007 17

2006 2

2005 2

open ︾

Keywords

1 15

Deep learning 10

2 6

Reinforcement learning 6

Machine learning 5

Multi-agent systems 4

PD-L1 4

hepatocellular carcinoma 4

1) 3

Multi-agent system 3

3 2

3-propanediol 2

4-Dioxane 2

Akkermansia muciniphila 2

Active learning 2

Adaptive dynamic programming 2

Artificial intelligence 2

Attention mechanism 2

Biodegradation 2

open ︾

Search scope:

排序： Display mode:

Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms

Frontiers of Medicine 2023, Volume 17, Issue 5,   Pages 805-822 doi: 10.1007/s11684-023-1025-7

Abstract: To date, immune checkpoint inhibitors (ICIs) of CTLA-4 and PD-1/PD-L1 represent the main class of immunotherapyBlockade of CTLA-4 and PD-1/PD-L1 has shown remarkable efficacy in several specific types of cancers,the generalized mechanism of targeting cancer metabolism at three crucial immune checkpoints (CTLA-4, PD-1-1, and PD-L1) to influence ICB therapy and propose potential combined immunotherapeutic strategies co-targeting

Keywords： CTLA-4     PD-1     PD-L1     immune checkpoint blockade (ICB)     metabolic reprogramming     combined tumor therapeutic    

HTML PDF Collect

PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives

Yumeng Wang, Guiling Li

Frontiers of Medicine 2019, Volume 13, Issue 4,   Pages 438-450 doi: 10.1007/s11684-018-0674-4

Abstract: Checkpoint blockades targeting the PD-1/PD-L1 axis have achieved effective clinical responses with acceptableIn this review, we summarize recent advances in our understanding of the PD-1/PD-L1 signaling pathway, including the expression patterns of PD-1/PD-L1 and potential PD-1/PD-L1-related therapeutic strategies

Keywords： PD-1     PD-L1     immune checkpoint blockade antibody     immunotherapy     cervical cancer    

HTML PDF Collect

Activation of phagocytosis by immune checkpoint blockade

Chia-Wei Li, Yun-Ju Lai, Jennifer L. Hsu, Mien-Chie Hung

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 473-480 doi: 10.1007/s11684-018-0657-5

Abstract: On the basis of a recently discovered programmed death protein 1 (PD-1) in TAMs, we discuss the potential

Keywords： CD47     PD-1     PD-L1     immunotherapy     TAM     phagocytosis     macrophage    

HTML PDF Collect

High-Affinity Decoy PD-1 Mutant Screened from an Epitope-Specific Cell Library Article

Hao Liu, Chunxia Qiao, Naijing Hu, Zhihong Wang, Jing Wang, Jiannan Feng, Beifen Shen, Yuanfang Ma, Longlong Luo

Engineering 2021, Volume 7, Issue 11,   Pages 1557-1565 doi: 10.1016/j.eng.2020.11.011

Abstract: The PD-1/PD-L1 pathway inhibits T cell activation in the micro-environment, making it anWild-type (WT) PD-1 ectodomain has been shown to have difficulty blocking PD-1/PD-L1 mixture formationBased on the theoretical binding analysis of PD-1 and its ligands (i.e., PD-L1 and PD-L2) or antibodyWT PD-1 to the PD-L1 (the affinity has increased by almost three orders of magnitude) was screened outIt exhibited an inhibitory effect against PD-1 to prevent it from forming mixtures with PD-L1, which

Keywords： Decoy PD-1     PD-L1     Mammalian cell library     Epitope-oriented    

HTML PDF Collect

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors

Yingyan Yu

Frontiers of Medicine 2018, Volume 12, Issue 2,   Pages 229-235 doi: 10.1007/s11684-017-0581-0

Abstract: refractory Hodgkin lymphoma, and urothelial carcinoma, all of which carry positive programmed death-1/programmed death-ligand 1 biomarkers.

Keywords： molecular classification     precision medicine     pembrolizumab     PD-1/PD-L1     MSI-H    

HTML PDF Collect

Dihydroartemisinin increased the abundance of by YAP1 depression that sensitizes hepatocellular carcinomato anti-PD-1 immunotherapy

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 729-746 doi: 10.1007/s11684-022-0978-2

Abstract: The effect of anti-programmed cell death 1 (anti-PD-1) immunotherapy is limited in patients with hepatocellularHere, anti-PD-1 treatment decreased A. muciniphila abundance in the colon, but increased YAP1Yap1 knockout enhanced anti-PD-1 efficacy.anti-PD-1 efficacy in liver tumors.anti-PD-1 therapy.

Keywords： hepatocellular carcinoma     YAP1     Akkermansia muciniphila     anti-PD-1     dihydroartemisinin     bile acid    

HTML PDF Collect

DNA Damage Response Inhibitor and Anti-PD-L1 Therapy for Prostate Cancer: Development of Predictive Biomarkers

Chuandong Geng,Timothy C. Thompson

Engineering 2022, Volume 12, Issue 5,   Pages 12-15 doi: 10.1016/j.eng.2022.01.002

HTML PDF Collect

Formic acid dehydrogenation reaction on high-performance PdxAu1−x

Frontiers in Energy 2023, Volume 17, Issue 6,   Pages 751-762 doi: 10.1007/s11708-023-0895-3

Abstract: Herein, the PdxAu1−x (x = 0, 0.2, 0.4, 0.5, 0.6, 0.8, 1) alloysowing to the strong metal-support interaction (SMSI) and electron transfer between active metal Au and Pd, the Pd0.5Au0.5 obtained exhibits a turnover frequency (TOF) value of up to 1648h−1 (313 K, nPd+Au/nFA = 0.01, nHCOOH/nHCOONa = 1:3) with a high activity, selectivity, and reusability in the FA dehydrogenation

Keywords： FA dehydrogenation     face-centred cubic structures     PdAu solid solution alloy nanoparticles     slow synthesis methodology     SMSI effect    

HTML PDF Collect

Synthesis, physicochemical characterizations and catalytic performance of Pd/carbon-zeolite and Pd/carbon-CeO

Zeinab JAMALZADEH, Mohammad HAGHIGHI, Nazli ASGARI

Frontiers of Environmental Science & Engineering 2013, Volume 7, Issue 3,   Pages 365-381 doi: 10.1007/s11783-013-0520-5

Abstract: In this work, xylene removal from waste gas streams was investigated via catalytic oxidation over Pd/carbon-zeolite and Pd/carbon-CeO nanocatalysts.

Keywords： Pd/carbon-CeO2     Pd/carbon-zeolite     pine cone     ZnCl2     catalytic oxidation     xylene    

HTML PDF Collect

Application of StrucGP in medical immunology: site-specific -glycoproteomic analysis of macrophages

Frontiers of Medicine 2023, Volume 17, Issue 2,   Pages 304-316 doi: 10.1007/s11684-022-0964-8

Abstract: In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-bisected GlcNAc, core fucosylated, and sialylated glycans (e.g., HexNAc4Hex5Fuc1Neu5Ac1, N4H5F1S1) were increased in M1 andIn addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moietywas detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.

Keywords： macrophage     glycoproteome     glycopeptides     N-glycan structures     PD-L1    

HTML PDF Collect

Promoting effect of Zr on the catalytic combustion of methane over Pd/γ-Al

Hongbo NA,Tianle ZHU,Zhiming LIU,Yifei SUN

Frontiers of Environmental Science & Engineering 2014, Volume 8, Issue 5,   Pages 659-665 doi: 10.1007/s11783-013-0613-1

Abstract: The effect of Zr on the catalytic performance of Pd/γ-Al O for the methane combustion was investigatedThe results show that the addition of Zr can improve the activity and stability of Pd/γ-Al O catalystThe active phase of methane combustion over supported palladium catalyst is the Pd /Pd mixture.Zr addition inhibits Pd aggregation and enhances the redox properties of active phase Pd / Pd .(Pd / Pd ).

Keywords： Pd-Zr/Al2O3     methane     catalytic combustion     catalyst regeneration    

HTML PDF Collect

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 32-44 doi: 10.1007/s11684-018-0678-0

Abstract:

Immunotherapy has become the fourth cancer therapy after surgery, chemotherapy, and radiotherapy. In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall survival rates of patients with refractory cancers, such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. However, inhibitor therapies are only effective in a small proportion of patients with problems, such as side effects and high costs. Therefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies to choose the optimal therapies. Here, we review the biomarkers that can serve as potential predictors of the outcomes of immune checkpoint inhibitor treatment, including tumor-specific profiles and tumor microenvironment evaluation and other factors.

Keywords： immune checkpoint     companion diagnosis     PD-L1     tumor mutation burden     immune score    

HTML PDF Collect

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Shi-Yong Sun

Frontiers of Medicine 2021, Volume 15, Issue 2,   Pages 221-231 doi: 10.1007/s11684-020-0812-7

Abstract: metabolism, survival, and immune response by forming two important complexes, namely, mTOR complex 1(mTORC1) and complex 2 (mTORC2). mTOR signaling is often dysregulated in cancers and has been consideredmade to develop efficacious mTOR inhibitors, particularly mTOR kinase inhibitors, which suppress mTORC1findings on the essential role of GSK3 in mediating cancer cell response to mTOR inhibitors and mTORC1inhibition-induced upregulation of PD-L1 in cancer cells may provide some explanations.

Keywords： mTOR     cancer therapy     resistance     GSK3     protein degradation     E3 ubiquitin ligase     PD-L1    

HTML PDF Collect

Electrocatalytic reduction of nitrate using Pd-Cu modified carbon nanotube membranes

Frontiers of Environmental Science & Engineering 2023, Volume 17, Issue 4, doi: 10.1007/s11783-023-1640-1

Abstract:

● Pd-Cu modified CNT membranes were prepared successfully by electrodeposition

Keywords： Pd-Cu modified CNT membrane     Nitrate reduction     Flow-through     Electrodeposition     Electrocatalytic reduction    

HTML PDF Collect

A comparison of the catalytic hydrogenation of 2-amylanthraquinone and 2-ethylanthraquinone over a Pd

Enxian Yuan, Xiangwei Ren, Li Wang, Wentao Zhao

Frontiers of Chemical Science and Engineering 2017, Volume 11, Issue 2,   Pages 177-184 doi: 10.1007/s11705-016-1604-0

Abstract: of 2-ethylanthraquinone (eAQ), 2- -amylanthraquinone (taAQ) and their mixtures with molar ratios of 1:1 and 1:2 to the corresponding hydroquinones (eAQH and taAQH ) were studied over a Pd/Al O catalystcan be ascribed to the longer and branched side chain in taAQ, which limits its accessibility to the PdDensity functional theory calculations showed that it is more difficult for taAQ to adsorb onto a Pd

Keywords： hydrogenation     hydrogen peroxide     anthraquinone     Pd catalyst     AO process    

HTML PDF Collect

Title Author Date Type Operation

Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms

Journal Article

PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives

Yumeng Wang, Guiling Li

Journal Article

Activation of phagocytosis by immune checkpoint blockade

Chia-Wei Li, Yun-Ju Lai, Jennifer L. Hsu, Mien-Chie Hung

Journal Article

High-Affinity Decoy PD-1 Mutant Screened from an Epitope-Specific Cell Library

Hao Liu, Chunxia Qiao, Naijing Hu, Zhihong Wang, Jing Wang, Jiannan Feng, Beifen Shen, Yuanfang Ma, Longlong Luo

Journal Article

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors

Yingyan Yu

Journal Article

Dihydroartemisinin increased the abundance of by YAP1 depression that sensitizes hepatocellular carcinomato anti-PD-1 immunotherapy

Journal Article

DNA Damage Response Inhibitor and Anti-PD-L1 Therapy for Prostate Cancer: Development of Predictive Biomarkers

Chuandong Geng,Timothy C. Thompson

Journal Article

Formic acid dehydrogenation reaction on high-performance PdxAu1−x

Journal Article

Synthesis, physicochemical characterizations and catalytic performance of Pd/carbon-zeolite and Pd/carbon-CeO

Zeinab JAMALZADEH, Mohammad HAGHIGHI, Nazli ASGARI

Journal Article

Application of StrucGP in medical immunology: site-specific -glycoproteomic analysis of macrophages

Journal Article

Promoting effect of Zr on the catalytic combustion of methane over Pd/γ-Al

Hongbo NA,Tianle ZHU,Zhiming LIU,Yifei SUN

Journal Article

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian

Journal Article

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Shi-Yong Sun

Journal Article

Electrocatalytic reduction of nitrate using Pd-Cu modified carbon nanotube membranes

Journal Article

A comparison of the catalytic hydrogenation of 2-amylanthraquinone and 2-ethylanthraquinone over a Pd

Enxian Yuan, Xiangwei Ren, Li Wang, Wentao Zhao

Journal Article